U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Cu
Molecular Weight 63.546
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 2

SHOW SMILES / InChI
Structure of CUPRIC CATION

SMILES

[Cu++]

InChI

InChIKey=JPVYNHNXODAKFH-UHFFFAOYSA-N
InChI=1S/Cu/q+2

HIDE SMILES / InChI

Molecular Formula Cu
Molecular Weight 63.546
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc | http://www.sciencedirect.com/science/article/pii/S0167488912000158https://www.ncbi.nlm.nih.gov/pubmed/16971307DOI: 10.1107/s0567740869001725 Retrived from http://scripts.iucr.org/cgi-bin/paper?S0567740869001725https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518 | http://www.worldofchemicals.com/chemicals/chemical-properties/cupric-glycinate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/8556785 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.ncbi.nlm.nih.gov/pubmed/15704330 | https://www.ncbi.nlm.nih.gov/pubmed/12425037 | https://www.ncbi.nlm.nih.gov/pubmed/1599240 | http://www.certisusa.com/pdf-labels/Kocide3000_label.pdf | http://www.pesticideinfo.org/Detail_Chemical.jsp?Rec_Id=PC33524http://www.emdmillipore.com/US/en/product/Copper-di-ammonium-Titriplex-solution,MDA_CHEM-105217http://www.drugfuture.com/chemdata/tetraamminecopper-sulfate.html | https://cameochemicals.noaa.gov/chemical/3026https://www3.epa.gov/pesticides/chem_search/ppls/019713-00509-20110705.pdfhttp://fs1.agrian.com/pdfs/CORE_7.5_Copper_EDTA_Label.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/6526221http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013010.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/24106015 | https://www.ncbi.nlm.nih.gov/pubmed/20942456http://www.drugfuture.com/chemdata/schweizer-s-reagent.html | http://pubs.acs.org/doi/abs/10.1021/ed062p878?journalCode=jceda8 | http://pubs.acs.org/doi/abs/10.1021/ed019p356
Curator's Comment: description was created based on several sources, including https://www.copper.org/resources/properties/compounds/other_compounds.html | http://www.vitamins-supplements.org/dietary-minerals/copper.php | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bea888b4-9cc6-49da-89e6-5c273b974ed1

Tetraamminecopper dihydroxide also known as Schweizer's Reagent dissolves cellulose; used in rayon production.

CNS Activity

Curator's Comment: Known to be CNS active in zebrafish. Human data not available.

Originator

Sources: http://pubs.acs.org/doi/abs/10.1021/ja01512a012Schweizer, J. Prakt. Chem. 72, 109, 344 (1857).
Curator's Comment: http://www.drugfuture.com/chemdata/schweizer-s-reagent.html

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Preventing
Cupric glycinate

Approved Use

Indications for use. For beef calves and beef cattle for the prevention of copper deficiency, or when labeled for veterinary prescription use, for the prevention and/or treatment of copper deficiency alone or in association with molybdenum toxicity.
Primary
COPPER•MAX

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Diagnostic
Unknown

Approved Use

Unknown
Preventing
COPPER

Approved Use

Copper 0.4 mg/mL (Cupric Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Preventing
COPINOX

Approved Use

Copinox 4g is indicated for the prevention and treatment of copper deficiency in cattle and sheep.
PubMed

PubMed

TitleDatePubMed
Acute copper toxicity following copper glycinate injection.
2006 Nov
Copper oxide nanoparticles induce oxidative stress and cytotoxicity in airway epithelial cells.
2009 Oct
Generation of oxidant response to copper and iron nanoparticles and salts: Stimulation by ascorbate.
2009 Oct 30
Insight in the transport behavior of copper glycinate complexes through the porcine gastrointestinal membrane using an Ussing chamber assisted by mass spectrometry analysis.
2010 Apr
Copper-promoted coupling of vinyl boronates and alcohols: a mild synthesis of allyl vinyl ethers.
2010 Feb 3
Regulation of plasminogen activator inhibitor-1 expression in endothelial cells with exposure to metal nanoparticles.
2010 May 19
A chelator-free multifunctional [64Cu]CuS nanoparticle platform for simultaneous micro-PET/CT imaging and photothermal ablation therapy.
2010 Nov 3
Zinc prevents the copper-induced damage of cultured astrocytes.
2010 Oct
Copper sulfide nanoparticles for photothermal ablation of tumor cells.
2010 Oct
Molecular responses of human lung epithelial cells to the toxicity of copper oxide nanoparticles inferred from whole genome expression analysis.
2011 Dec 27
Expeditious synthesis of phenanthrenes via CuBr2-catalyzed coupling of terminal alkynes and N-tosylhydrazones derived from o-formyl biphenyls.
2011 Oct 7
Zeta potential and solubility to toxic ions as mechanisms of lung inflammation caused by metal/metal oxide nanoparticles.
2012 Apr
Protective effect of sulphoraphane against oxidative stress mediated toxicity induced by CuO nanoparticles in mouse embryonic fibroblasts BALB 3T3.
2012 Feb
Probing the chemical nature of dihydrogen complexation to transition metals, a gas phase case study: H2-CuF.
2013 Jan 18
Design, synthesis, antioxidant, and anti-breast cancer activities of novel diethyl(alkyl/aryl/heteroarylamino)(4-(pyridin-2-yl)phenyl)methylphosphonates.
2013 May
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
The modality of cell-particle interactions drives the toxicity of nanosized CuO and TiO₂ in human alveolar epithelial cells.
2013 Oct 24
Interference of CuO nanoparticles with metal homeostasis in hepatocytes under sub-toxic conditions.
2014
A Facile Strategy for Catalyst Separation and Recycling Suitable for ATRP of Hydrophilic Monomers Using a Macroligand.
2016 Jan
Dissecting copper homeostasis in diabetes mellitus.
2017 Apr
Unusual 4-arsonoanilinium cationic species in the hydrochloride salt of (4-aminophenyl)arsonic acid and formed in the reaction of the acid with copper(II) sulfate, copper(II) chloride and cadmium chloride.
2017 Apr 1
Supplementation with copper edetate in control of Haemonchus contortus of sheep, and its effect on cholinesterase's and superoxide dismutase activities.
2017 Feb
Ultrasonic energy enhanced the efficiency of advance extraction methodology for enrichment of trace level of copper in serum samples of patients having neurological disorders.
2017 Jul
Comparison of the efficacy of a commercial footbath product with copper sulfate for the control of digital dermatitis.
2017 Jul
Patents

Sample Use Guides

In Vivo Use Guide
Copper 0.4 mg/mL (Cupric Chloride Injection) contains 0.4 mg copper/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving total parenteral nutrition, the suggested additive dosage is 0.5 to 1.5 mg copper/day (1.25 to 3.75 mL/day). For pediatric patients, the suggested additive dosage is 20 mcg copper/kg/day (0.05 mL/kg/day). Infants weighing less than 1500 gm may have increased requirements because of their low body reserves and increased requirements for growth.
Route of Administration: Intravenous
Human Endometrial Stromal Cells were treated with non-toxic concentrations of copper ions (0-250 uM). mRNA expressions of insulin-like growth factor binding protein (IGFBP-1), prolactin (PRL), Mn-SOD, and FOXO1 were down-regulated during decidualization following the treatments with 100 or 250 uM copper ions. Meanwhile, the amount of malonaldehyde in the supernatant of cells was increased.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:28:28 GMT 2023
Edited
by admin
on Fri Dec 15 15:28:28 GMT 2023
Record UNII
8CBV67279L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CUPRIC CATION
Common Name English
COPPER, ION (CU2+)
Common Name English
COPPER(II) ION
Common Name English
COPPER(II) CATION
Common Name English
CUPRIC ION
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C68249
Created by admin on Fri Dec 15 15:28:29 GMT 2023 , Edited by admin on Fri Dec 15 15:28:29 GMT 2023
FDA ORPHAN DRUG 771520
Created by admin on Fri Dec 15 15:28:29 GMT 2023 , Edited by admin on Fri Dec 15 15:28:29 GMT 2023
Code System Code Type Description
CAS
15158-11-9
Created by admin on Fri Dec 15 15:28:29 GMT 2023 , Edited by admin on Fri Dec 15 15:28:29 GMT 2023
PRIMARY
DAILYMED
8CBV67279L
Created by admin on Fri Dec 15 15:28:29 GMT 2023 , Edited by admin on Fri Dec 15 15:28:29 GMT 2023
PRIMARY
RXCUI
1427198
Created by admin on Fri Dec 15 15:28:29 GMT 2023 , Edited by admin on Fri Dec 15 15:28:29 GMT 2023
PRIMARY RxNorm
EPA CompTox
DTXSID40934294
Created by admin on Fri Dec 15 15:28:29 GMT 2023 , Edited by admin on Fri Dec 15 15:28:29 GMT 2023
PRIMARY
PUBCHEM
27099
Created by admin on Fri Dec 15 15:28:29 GMT 2023 , Edited by admin on Fri Dec 15 15:28:29 GMT 2023
PRIMARY
SMS_ID
100000087380
Created by admin on Fri Dec 15 15:28:29 GMT 2023 , Edited by admin on Fri Dec 15 15:28:29 GMT 2023
PRIMARY
CHEBI
29036
Created by admin on Fri Dec 15 15:28:29 GMT 2023 , Edited by admin on Fri Dec 15 15:28:29 GMT 2023
PRIMARY
NCI_THESAURUS
C68251
Created by admin on Fri Dec 15 15:28:29 GMT 2023 , Edited by admin on Fri Dec 15 15:28:29 GMT 2023
PRIMARY
FDA UNII
8CBV67279L
Created by admin on Fri Dec 15 15:28:29 GMT 2023 , Edited by admin on Fri Dec 15 15:28:29 GMT 2023
PRIMARY
DRUG BANK
DB09130
Created by admin on Fri Dec 15 15:28:29 GMT 2023 , Edited by admin on Fri Dec 15 15:28:29 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
LIGAND->TARGET
Scientific Literature
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY